Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
Portfolio Pulse from
VolitionRx Limited has signed an agreement with a leading pharmaceutical company to use its Nu.Q® Discover biomarkers in a Phase 1/2b clinical study. This marks the first time these biomarkers will be used in a human clinical study.
March 04, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VolitionRx Limited has entered into a significant agreement with a leading pharmaceutical company to use its Nu.Q® Discover biomarkers in a human clinical study, marking a milestone for the company.
The agreement to use Nu.Q® Discover biomarkers in a human clinical study is a significant milestone for VolitionRx, potentially increasing the company's visibility and credibility in the pharmaceutical industry. This could positively impact VNRX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100